News Poxel taking two shots at NASH as pharma waits on FDA's OCA ... Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NA
News Trial sets up 2020 filing for Poxel's novel diabetes drug French biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 diabetes, setting up a first filing in Japan next year.
News Ramaswamy's Roivant signs diabetes drug deal with Poxel Biotech entrepreneur hopes to bounce back from Alzheimer's disappointment
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face